FDA generic division overhaul kicks in

Share this article:

The FDA's effort to overhaul its generics division is finally taking shape. Regulatory Focus reports that the Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012, but problems, such as staff turnover, have slowed things down, just as the importance of generic drugs in the US has accelerated.

RF stumbled across a low-key FDA announcement dated Monday that highlights some pretty significant changes, including four new division offices—research and standards, bioequivalence, generic drug policy and regulatory operations—and three new leaders.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.